The latest trading update reveals a significantly improved financial position for Fusion compared to the previous year. Unaudited sales have surged by 73% to £1.96m, a substantial increase from the £1.14m reported last year. Notably, the update indicates revenue of £0.72m for 2H’25, aligning closely with our previous FY’25 forecast of £1.99m from Shard’s investor meeting (24/09/24) During this period, Fusion successfully secured two significant grants: the Future Medicines Institute grant, provi ....
